Securities code: Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) securities abbreviation: Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) Announcement No.: 2022034
Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089)
First quarter report 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions. Important content tips:
1. The board of directors, the board of supervisors, directors, supervisors and senior managers guarantee that the quarterly report is true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
2. The person in charge of the company, the person in charge of accounting and the person in charge of the accounting organization (Accounting Supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
3. The first quarter report was unaudited. 1、 Main financial data (I) main accounting data and financial indicators does the company need to retroactively adjust or restate the accounting data of previous years □ yes √ no
Increase or decrease in the reporting period compared with the same period of the previous year
Operating income (yuan): 1295494595714429632322 – 10.22%
Net profit attributable to shareholders of the listed company (yuan) 28439239023011586350 – 5.57%
Net profit attributable to shareholders of listed companies after deducting non recurring losses of 2647111735, 2877048442 – 7.99% (yuan)
Net cash flow from operating activities (yuan) -3072039332275289785 -113.50%
Basic earnings per share (yuan / share) 0.23 0.32 – 28.13%
Diluted earnings per share (yuan / share) 0.23 0.32 – 28.13%
Weighted average return on net assets 2.56%, 6.00% – 3.44%
Increase or decrease at the end of the reporting period compared with the end of the previous year
Total assets (yuan): 140096199016139371153179 0.52%
Owner’s equity attributable to shareholders of the listed company (yuan) 112579887633109735963730 2.59%
（2） Non recurring profit and loss items and amount √ applicable □ not applicable
Unit: Yuan
Description of the amount of the project in the current reporting period
Gains and losses on disposal of non current assets (including the write off part of the provision for asset impairment) – 42544722
Government subsidies included in current profits and losses (closely related to the company’s normal business, conforming to 282077833)
Government subsidies that comply with national policies and regulations and are continuously enjoyed according to a certain standard, quota or quota
(excluding AIDS)
Other non operating income and expenses other than the above 227424
Less: income tax impact 42948368
Total 196812167–
Details of other profit and loss items that meet the definition of non recurring profit and loss: □ applicable √ not applicable. The company does not have details of other profit and loss items that meet the definition of non recurring profit and loss. Description of defining the non recurring profit and loss items listed in the explanatory announcement on information disclosure of companies offering securities to the public No. 1 – non recurring profit and loss as recurring profit and loss items □ applicable √ not applicable the company does not define the non recurring profit and loss items listed in the explanatory announcement on Information Disclosure of companies offering securities to the public No. 1 – non recurring profit and loss as recurring profit and loss items. （3） Changes and reasons of major accounting data and financial indicators √ applicable □ not applicable 1. Major changes and reasons of items in the consolidated balance sheet
Reasons for the change in the proportion of the project from March 31, 2022 to December 31, 2021
Advance payment 1111322082756061354 46.99% was mainly due to the increase of epidemic logistics restrictions
Due to the reserve of raw materials.
Other receivables 30804445 and 16197414 accounted for 90.18%, mainly due to the increase of petty cash.
191533185% – 100.00% of the non current assets due within one year are mainly the guarantee to recover the due assets in the current period
Caused by gold
Long term equity investment 145107820105096066 38.05%, mainly due to the increase of subsidiary Xinxiang pharmaceutical
Foreign investment.
46712671363558911185 and 31.26% of the projects under construction are mainly raised by the subsidiary Xinxiang pharmaceutical
Due to the investment of the project.
Deferred income tax assets 849904958651007100 30.55% are mainly due to unrealized internal transactions in the current period
Profit offset.
The tax payable is 853553503270618943 215.41%, mainly due to the income accrued at the end of the period
Due to tax increase
490577110% – 100.00% of the non current liabilities due within one year are mainly from the sale and leaseback business in the current period
Due to overdue return.
Mainly due to the decrease in advance payment for domestic sales,
Other current liabilities 1933174836802079 – 47.47% related “output tax to be transferred” decreased
Caused by.
2. Major changes in consolidated income statement items and reasons
Reasons for the change in the proportion of the project from January to March 2022 and from January to March 2021
Administrative expenses 182 Zhejiang Founder Motor Co.Ltd(002196) 11257581401 44.72% are mainly due to employee compensation, depreciation and
Due to the increase of agency and other expenses.
Financial expenses -50870335268591148 – 118.94% were mainly due to the decrease of bank borrowings and interest
Due to reduced costs.
Other income 282077833159575461 76.77% is mainly government subsidies received in the current period
Increase.
Investment income (loss expressed with “-“) 1269212624085903095748%, mainly due to the maturity of bank structured deposits
Due to recognized income.
Credit impairment loss (loss is marked with “-” 98966982 -63810270 – 255.10%), mainly due to the guarantee of long-term receivables in the current period
It is caused by the recovery of bad debt reserves and the reversal of bad debt reserves.
Asset impairment loss (loss expressed with “-” mainly refers to inventory withdrawn in the same period of last year)
(fill in with)
